On-treatment modified Glasgow Prognostic Score (mGPS) in hepatocellular carcinoma treated with atezolizumab and bevacizumab provides prognostic information
The on-treatment mGPS, as well as ACR and AIR, predicted outcomes in patients with HCC independent of and more accurately than radiological staging. Since, the mGPS is the most cost effective and widely validated score, we consider it best suited for clinical use. Prospective validation is needed to confirm these findings.
Authors
- Peter Brossart (ORCID: https://orcid.org/0009-0002-9324-5527)
- Rebekka Mispelbaum (ORCID: https://orcid.org/0009-0000-6891-8705)
- Jonas Saal (ORCID: https://orcid.org/0000-0002-9647-2947)
- Tessa Hattenhauer (ORCID: https://orcid.org/0009-0001-3320-8815)
- Katjana Schwab (ORCID: https://orcid.org/0000-0002-6916-2900)
- Annkristin Heine (ORCID: https://orcid.org/0000-0002-5298-9880)
- Niklas Klümper (ORCID: https://orcid.org/0000-0002-3258-0586)
Institutions
- University Hospital Bonn (DE)
- Integrated Oncology (United States) (US)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2025-10-09
- DOI
- https://doi.org/10.3389/fimmu.2025.1599143
- Primary Topic
- Liver Disease Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00